Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals and Sanofi have shared positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE), in which the trial met both co-primary endpoints.
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.
Regeneron Pharmaceuticals and Sanofi got the approval from the FDA for Dupixent for certain combinations to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.
Diplomat Pharmacy will sell Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab), recently approved by the FDA to treat adults with moderately to severely active rheumatoid arthritis (RA) who have an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs).
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).